Net revenue grew 3.5% to CHF 582.7 million in H1 2026, with strong organic growth in Healthcare and successful integration of Capsul'in. Margins improved, and the company reaffirmed midterm targets, expecting further gains as transformation and portfolio initiatives progress.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.